Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Contineum Therapeutics, Inc.CTNM · Entity 5311 | Chief Scientific Officer | July 08, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Contineum Therapeutics, Inc.
Report date July 08, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 135,202 |
Ending reported balance
After 2026-07-09 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-07-08 · Exercise / conversion · Acquired 1,015 · Balance 136,217 F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Row 2 · 2026-07-08 · Sale · Disposed 1,015 · Balance 135,202 F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Row 3 · 2026-07-09 · Exercise / conversion · Acquired 25 · Balance 135,227 F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Row 4 · 2026-07-09 · Sale · Disposed 25 · Balance 135,202 F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2030-02-24 | Direct | 33,282 |
Reported balance
After 2026-07-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-08 · Exercise / conversion · Disposed 1,015 · Balance 33,282 F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2: The stock options are fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2030-02-24 | Direct | 33,257 |
Reported balance
After 2026-07-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-09 · Exercise / conversion · Disposed 25 · Balance 33,257 F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2: The stock options are fully vested and exercisable. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Spouse | 10,110 |
Reported balance
Holding disclosure · report date 2026-07-08 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,110 |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
F2: The stock options are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 10, 2026 21:20 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 25 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001628280-26-047909 · wk-form4_1783718438.xml · derivative · entry 7 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,257 Underlying: Class A Common Stock · 25 shares Expires 2030-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · derivative.exercise_date: The stock options are fully vested and exercisable. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 21:20 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 25 | $16.00 | $400.00 |
DisclosureSEC source: 0001628280-26-047909 · wk-form4_1783718438.xml · nonDerivative · entry 4 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,202 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 21:20 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 25 | $1.01 | $25.25 |
DisclosureSEC source: 0001628280-26-047909 · wk-form4_1783718438.xml · nonDerivative · entry 3 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 21:20 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 1,015 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001628280-26-047909 · wk-form4_1783718438.xml · derivative · entry 6 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,282 Underlying: Class A Common Stock · 1,015 shares Expires 2030-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · derivative.exercise_date: The stock options are fully vested and exercisable. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 21:20 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 1,015 | $16.00 | $16,240.00 |
DisclosureSEC source: 0001628280-26-047909 · wk-form4_1783718438.xml · nonDerivative · entry 2 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,202 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 21:20 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 1,015 | $1.01 | $1,025.15 |
DisclosureSEC source: 0001628280-26-047909 · wk-form4_1783718438.xml · nonDerivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:47 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 4,183 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001628280-26-047058 · wk-form4_1783028831.xml · derivative · entry 8 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,297 Underlying: Class A Common Stock · 4,183 shares Expires 2030-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F6 · derivative.exercise_date: The stock options are fully vested and exercisable. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:47 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 2,501 | $16.24 | $40,608.49 |
DisclosureSEC source: 0001628280-26-047058 · wk-form4_1783028831.xml · nonDerivative · entry 5 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,202 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.16 to $16.40, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:47 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 5,852 | $15.67 | $91,681.53 |
DisclosureSEC source: 0001628280-26-047058 · wk-form4_1783028831.xml · nonDerivative · entry 4 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,703 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.15 to $16.14, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:47 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 4,183 | $1.01 | $4,224.83 |
DisclosureSEC source: 0001628280-26-047058 · wk-form4_1783028831.xml · nonDerivative · entry 3 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 21:47 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 28,826 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001628280-26-047058 · wk-form4_1783028831.xml · derivative · entry 7 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,480 Underlying: Class A Common Stock · 28,826 shares Expires 2030-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F6 · derivative.exercise_date: The stock options are fully vested and exercisable. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 21:47 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 28,826 | $16.04 | $462,288.33 |
DisclosureSEC source: 0001628280-26-047058 · wk-form4_1783028831.xml · nonDerivative · entry 2 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,372 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.35, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 21:47 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 28,826 | $1.01 | $29,114.26 |
DisclosureSEC source: 0001628280-26-047058 · wk-form4_1783028831.xml · nonDerivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| June 01, 2026 Filed Jun 1, 2026 22:08 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 4,170 | $13.16 | $54,862.19 |
DisclosureSEC source: 0001628280-26-039641 · wk-form4_1780351717.xml · nonDerivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,372 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.995 to $13.360, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 01, 2026 Filed May 1, 2026 21:42 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 300 | $13.84 | $4,152.00 |
DisclosureSEC source: 0001628280-26-029435 · wk-form4_1777671753.xml · nonDerivative · entry 2 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,542 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.79 to $13.86, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 01, 2026 Filed May 1, 2026 21:42 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 3,870 | $13.06 | $50,542.20 |
DisclosureSEC source: 0001628280-26-029435 · wk-form4_1777671753.xml · nonDerivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,842 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.69 to $13.57, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| April 06, 2026 Filed Apr 6, 2026 21:43 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 4,170 | $13.43 | $56,013.94 |
DisclosureSEC source: 0001628280-26-023949 · wk-form4_1775511809.xml · nonDerivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,712 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.08 to $13.60, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:30 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 4,170 | $15.01 | $62,585.03 |
DisclosureSEC source: 0001437749-26-006422 · rdgdoc.xml · nonDerivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,882 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.41, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 21:39 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 3,824 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001437749-26-005889 · rdgdoc.xml · derivative · entry 7 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,306 Underlying: Class A Common Stock · 3,824 shares Expires 2030-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F4 · derivative.exercise_date: The stock options are fully vested and exercisable. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 21:39 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 3,824 | $16.01 | $61,227.98 |
DisclosureSEC source: 0001437749-26-005889 · rdgdoc.xml · nonDerivative · entry 4 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,052 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 21:39 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 3,824 | $1.01 | $3,862.24 |
DisclosureSEC source: 0001437749-26-005889 · rdgdoc.xml · nonDerivative · entry 3 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:39 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 4,300 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001437749-26-005889 · rdgdoc.xml · derivative · entry 6 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,130 Underlying: Class A Common Stock · 4,300 shares Expires 2030-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F4 · derivative.exercise_date: The stock options are fully vested and exercisable. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:39 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 4,300 | $16.03 | $68,935.88 |
DisclosureSEC source: 0001437749-26-005889 · rdgdoc.xml · nonDerivative · entry 2 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,052 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:39 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 4,300 | $1.01 | $4,343.00 |
DisclosureSEC source: 0001437749-26-005889 · rdgdoc.xml · nonDerivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:05 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 100 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001437749-26-004912 · rdgdoc.xml · derivative · entry 4 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,430 Underlying: Class A Common Stock · 100 shares Expires 2030-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · derivative.exercise_date: The stock options are fully vested and exercisable. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:05 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 100 | $16.00 | $1,600.00 |
DisclosureSEC source: 0001437749-26-004912 · rdgdoc.xml · nonDerivative · entry 2 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,052 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:05 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 100 | $1.01 | $101.00 |
DisclosureSEC source: 0001437749-26-004912 · rdgdoc.xml · nonDerivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:26 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 400 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001437749-26-004122 · rdgdoc.xml · derivative · entry 4 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,530 Underlying: Class A Common Stock · 400 shares Expires 2030-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · derivative.exercise_date: The stock options are fully vested and exercisable. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:26 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 400 | $16.00 | $6,400.00 |
DisclosureSEC source: 0001437749-26-004122 · rdgdoc.xml · nonDerivative · entry 2 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,052 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:26 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 400 | $1.01 | $404.00 |
DisclosureSEC source: 0001437749-26-004122 · rdgdoc.xml · nonDerivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:24 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 1,170 | $15.25 | $17,836.77 |
DisclosureSEC source: 0001437749-26-003212 · rdgdoc.xml · nonDerivative · entry 2 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,052 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.12 to $15.45, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:24 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 3,000 | $14.82 | $44,468.70 |
DisclosureSEC source: 0001437749-26-003212 · rdgdoc.xml · nonDerivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,222 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $15.08, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 30, 2026 Filed Jan 30, 2026 21:54 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001437749-26-002576 · rdgdoc.xml · derivative · entry 2 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 6,500 Underlying: Class A Common Stock · 6,500 shares Expires 2036-01-29 F2 · derivative.exercise_date: Options granted under the Plan in connection with Reporting Person's spouse's continuous service at the Company. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's spouse's continuous service. Read SEC document |
| January 30, 2026 Filed Jan 30, 2026 21:54 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001437749-26-002576 · rdgdoc.xml · derivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Class A Common Stock · 160,000 shares Expires 2036-01-29 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"). The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 21:16 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 500 | $11.13 | $5,564.90 |
DisclosureSEC source: 0001437749-26-000616 · rdgdoc.xml · nonDerivative · entry 2 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,222 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.34, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 21:16 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 3,670 | $10.35 | $37,978.26 |
DisclosureSEC source: 0001437749-26-000616 · rdgdoc.xml · nonDerivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,722 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.000 to $10.955, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 21:10 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 4,170 | $12.23 | $51,009.11 |
DisclosureSEC source: 0001437749-25-038936 · rdgdoc.xml · nonDerivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,392 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.38, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 31, 2025 Filed Jan 31, 2025 21:38 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 3,700 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001437749-25-002431 · rdgdoc.xml · derivative · entry 2 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 3,700 Underlying: Class A Common Stock · 3,700 shares Expires 2035-01-30 F2 · derivative.exercise_date: Options granted under the Plan in connection with Reporting Person's spouse's continuous service at the Company. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's spouse's continuous service. Read SEC document |
| January 31, 2025 Filed Jan 31, 2025 21:38 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001437749-25-002431 · rdgdoc.xml · derivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Class A Common Stock · 110,000 shares Expires 2035-01-30 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"). 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 22:06 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 1,010 | $16.02 | $16,177.37 |
DisclosureSEC source: 0001437749-24-036349 · rdgdoc.xml · nonDerivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,562 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on August 19, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.14, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 22:07 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 99 | $17.05 | $1,687.95 |
DisclosureSEC source: 0001437749-24-035887 · rdgdoc.xml · nonDerivative · entry 2 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,572 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on August 19, 2024. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 22:07 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 6,091 | $16.37 | $99,732.82 |
DisclosureSEC source: 0001437749-24-035887 · rdgdoc.xml · nonDerivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,671 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on August 19, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.03 to $17.02, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 24, 2024 Filed May 29, 2024 21:58 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 3,700 | $0.00 Strike: $15.76 | $0.00 |
DisclosureSEC source: 0001437749-24-018624 · rdgdoc.xml · derivative · entry 2 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 3,700 Underlying: Class A Common Stock · 3,700 shares Expires 2034-05-23 F2 · derivative.exercise_date: Options granted under the Plan. 25% of the option shares vest on April 5, 2025, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's spouse's continuous service. Read SEC document |
| May 24, 2024 Filed May 29, 2024 21:58 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $15.76 | $0.00 |
DisclosureSEC source: 0001437749-24-018624 · rdgdoc.xml · derivative · entry 1 Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Class A Common Stock · 100,000 shares Expires 2034-05-23 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"). 25% of the option shares vest on April 5, 2025, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.